6-MONTH STUDY OF TROGLITAZONE (CI-991) IN PATIENTS WITH NIDDM

$19,613M01FY2001RRNIH

University Of Rochester, Rochester NY

Investigators

Linked publications & trials

Paper 37567038 Paper 35728925 Paper 33759672 Paper 33478957 Paper 33002231 Paper 32446491 Paper 31570296 Paper 31554845 Paper 31505070 Paper 31404238 Paper 30381795 Paper 29872859 Paper 28279433 Paper 28199816 Paper 27923864 Paper 27839954 Paper 27601618 Paper 27423510 Paper 27074126 Paper 26080344 Paper 25862953 Paper 25422979 Paper 25377444 Paper 25367540 Paper 25061144 Paper 24471562 Paper 24378638 Paper 24370654 Paper 24322171 Paper 24144899 Paper 24135709 Paper 23944767 Paper 23646844 Paper 23615642 Paper 23503447 Paper 23370608 Paper 23255294 Paper 23080542 Paper 23055555 Paper 22981277 Paper 22871201 Paper 22684193 Paper 22644414 Paper 22499082 Paper 22415562 Paper 22257000 Paper 22180621 Paper 22113871 Paper 22083073 Paper 22059091 Paper 22018086 Paper 21960671 Paper 21956833 Paper 21941167 Paper 21930284 Paper 21900636 Paper 21798559 Paper 21382516 Paper 21364200 Paper 21293986 Paper 21233301 Paper 21181521 Paper 21149431 Paper 21135351 Paper 20921898 Paper 20871389 Paper 20827170 Paper 20711481 Paper 20650002 Paper 20647396 Paper 20622678 Paper 20601666 Paper 20592644 Paper 20581335 Paper 20542294 Paper 20507211 Paper 20467286 Paper 20439846 Paper 20400411 Paper 20356575 Paper 20298818 Paper 20237308 Paper 20218880 Paper 20211581 Paper 20192725 Paper 20088693 Paper 20063429 Paper 20025358 Paper 19948631 Paper 19938945 Paper 19934383 Paper 19890073 Paper 19779585 Paper 19770624 Paper 19755933 Paper 19750543 Paper 19713112 Paper 19690614 Paper 19597072 Paper 19536490

Abstract

The primary objective of this study is to assess the efficacy of troglitazone in achieving glycemic control by comparing the fasting serum levels of hemoglobin A1c (HbA1c) and of glucose (FSG) in patients treated with placebo or troglitazone.

View original record on NIH RePORTER →